Search PEN
Penumbra Inc
NYSE · CIK 1321732
Last close317.55
Daily change-0.45 (-0.14%)
10 Years gain+327.50%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PEN · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
79.0Momentum
100.0Acceleration
100.0Confidence
89.0Annual Revenue13
Quarterly Revenue57
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.8 / 25
Quality19.4 / 25
Capital Efficiency11.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics7.7 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 4.1865 percentage points.
Operating leverageOperating margin improved by 11.0099 percentage points.
ROIC expansionROIC improved by 13.4424 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM21.25%OK
Revenue CAGR 3Y18.33%OK
Gross Margin67.36%OK
Operating Margin11.58%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC13.87%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.04%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.40B | $942.44M | $189.25M | $238.66M | $174.93M | 67.14% | 13.48% | 12.46% | 19.36% | 39.29M |
| 2025 FY Dec 31, 2024 | $1.19B | $755.00M | $9.28M | $168.48M | $147.30M | 63.2% | 0.78% | 12.33% | 0.73% | 39.27M |
| 2025 FY Dec 31, 2023 | $1.06B | $682.64M | $73.55M | $97.33M | $82.12M | 64.49% | 6.95% | 7.76% | 7.42% | 39.22M |
| 2024 FY Dec 31, 2022 | $847.13M | $535.21M | $6.08M | -$55.66M | -$74.96M | 63.18% | 0.72% | -8.85% | 0.52% | 37.84M |
| 2023 FY Dec 31, 2021 | $747.59M | $475.38M | -$7.50M | $9.50M | -$11.68M | 63.59% | -1% | -1.56% | -1.1% | 37.88M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.46B | sum latest 4 fiscal quarters Revenue | OK | 0001321732-26-000037, 0001321732-25-000109 |
| Revenue Growth TTM | 21.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001321732-26-000037, 0001321732-25-000109 |
| Revenue CAGR 3Y | 18.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001321732-26-000007 |
| Revenue CAGR 5Y | 20.16% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001321732-26-000007 |
| Gross Profit CAGR 3Y | 20.76% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001321732-26-000007 |
| Operating Income Growth | 2,364.82% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001321732-26-000037, 0001321732-25-000109 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 67.36% | Gross Profit / Revenue | OK | 0001321732-26-000037, 0001321732-25-000109 |
| Operating Margin | 11.58% | Operating Income / Revenue | OK | 0001321732-26-000037, 0001321732-25-000109 |
| ROIC | 13.87% | NOPAT / Average Invested Capital | OK | 0001321732-26-000037, 0001321732-25-000109 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001321732-26-000037 |
| Current Ratio | 5.75x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $36.87 | Revenue / Diluted Shares | OK | 0001321732-26-000037, 0001321732-25-000109 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |